Synaptogenix to Present at the Cell Symposium

Rhea-AI Summary

Synaptogenix, a biopharmaceutical company focused on neurodegenerative disorders, announced that Dr. Daniel Alkon will present at the Cell Symposium in Spain on May 17, 2022. The presentation is titled "Bryostatin Enhances Synaptic Growth through Epigenetic Regulation of ApoE Alleles." This research aims to extend the therapeutic benefits of Bryostatin for Alzheimer's patients. Currently, the company is conducting a NIH-supported Phase 2 trial for advanced Alzheimer's patients who have shown improvement with Bryostatin treatment.

NEW YORK, May 17, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will have a presentation at the Cell Symposium conference in Sitges, Spain on Tuesday, May 17^th. The title of the poster is "Bryostatin Enhances Synaptic Growth through Epigenetic Regulation of ApoE Alleles." 

"We are excited to present at this event sponsored by Cell Press, one of the leading scientific publications in our space. Through direct regulation of the Alzheimer's disease ("AD") major risk genes (called ApoE), we may be able to extend Bryostatin's therapeutic benefits to a prevention, pre-dementia strategy.  Synaptogenix is currently conducting a six-month, National Institutes of Health ("NIH") supported Phase 2 trial for advanced AD patients who have previously shown actual improvement over baseline with Bryostatin treatment." stated Dr. Daniel Alkon, President and Chief Scientific Officer.     

Additional information can be found at the Cell Symposia website.

About Synaptogenix, Inc.

Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in AD. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease, Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs. Additional information about Synaptogenix, Inc. may be found on its website: www.synaptogen.com .

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 clinical trial of Bryostatin-1 and further studies, and continued development of use of Bryostatin-1 for AD and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand its business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement its business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.

Contact information:
Investors and Media 

800-811-5591
ir@synaptogen.com

Robert Weinstein
Chief Financial Officer
Synaptogenix, Inc.
rweinstein@synaptogen.com

View original content:https://www.prnewswire.com/news-releases/synaptogenix-to-present-at-the-cell-symposium-301549057.html

SOURCE Synaptogenix, Inc.

FAQ

What will Synaptogenix present at the Cell Symposium on May 17, 2022?

Synaptogenix will present on the poster titled "Bryostatin Enhances Synaptic Growth through Epigenetic Regulation of ApoE Alleles."

Who is presenting for Synaptogenix at the Cell Symposium?

Dr. Daniel Alkon, President and Chief Scientific Officer, will present for Synaptogenix.

What is the focus of Synaptogenix's research regarding Bryostatin?

The research focuses on extending Bryostatin's therapeutic benefits to a prevention strategy for Alzheimer's disease.

What type of clinical trial is Synaptogenix currently conducting for Bryostatin?

Synaptogenix is conducting a NIH-supported Phase 2 trial for advanced Alzheimer's patients.

What is the significance of the ApoE alleles in Synaptogenix's research?

ApoE alleles are major risk genes for Alzheimer's disease, and their regulation is crucial for Bryostatin's therapeutic application.